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AbstrACt
Introduction Prolonged use of antivirals to prevent the 
development of cytomegalovirus (CMV) disease in lung 
transplant patients has been shown to have significant 
side effects, for which alternatives are being sought to 
reduce their use. The monitoring of cell immunity against 
CMV could be an alternative as it has shown to be useful 
in identifying transplant patients at low risk of infection, 
who could benefit from shorter prophylaxis. The aim of the 
CYTOCOR study is to demonstrate that the combination 
of a reduced prophylaxis strategy with subsequent CMV-
specific immunological monitoring would allow CMV 
infection to be controlled in lung transplant patients as 
effectively as the usual strategy (prophylaxis followed by 
pre-emptive therapy), while reducing the side effects of 
antivirals due to the shorter duration of prophylaxis.
Methods and analysis Phase III randomised, open, 
multicentre, parallel, non-inferiority clinical trial to study 
the efficacy and safety of the combination of a prophylaxis 
strategy up to month +3 post-transplant followed by 
immuno-guided prophylaxis using the QuantiFERON-CMV 
technique up to month +12 post-transplant to prevent CMV 
disease in CMV-seropositive lung transplant recipients. 
This strategy will be compared with a combination of a 
usual prophylaxis strategy up to month +6 post-transplant 
followed by pre-emptive therapy up to month +12. To 
study the incidence of CMV disease, patients will be 
followed up to 18 months post-transplantation. A total of 
150 patients are expected to be recruited for the study.
Ethics and public dissemination The clinical trial has 
been approved by the Research Ethics Committees and 
authorised by the Spanish Agency of Medicines and 
Medical Devices (AEMPS).
If the hypothesis of this clinical trial is verified, the 
dissemination of the results could change clinical practice 
by increasing knowledge about the safety and efficacy of 
discontinuing valganciclovir prophylaxis in lung transplant 
recipients.
trial registration number NCT03699254.
IntroduCtIon
Cytomegalovirus (CMV) infection is a signifi-
cant cause of morbidity and mortality in solid 
organ transplant (SOT) patients. The risk of 
strengths and limitations of this study
 ► If the hypothesis of this clinical trial is confirmed, 
the usual clinical practice for the management of 
cytomegalovirus (CMV) in lung transplant recipients 
could be modified by incorporating the monitoring 
of specific cell immunity against this virus, which 
would allow for the better identification of patients 
at risk of CMV disease.
 ► It would also reduce the time of antiviral prophylaxis 
in many of these patients with CMV-specific immu-
nity and therefore prevent or limit the adverse ef-
fects of this antiviral and lead to economic savings.
 ► The main limitation of this study is the complexity 
of the design of the clinical trials, which can hinder 
the inclusion and follow-up of candidates. For this 
reason, a sample size has been calculated assuming 
a 5% loss to follow-up and a conservative inclusion 
rate in the estimated time.
 ► Another limitation is the QuantiFERON-CMV tech-
nique, as this technique only measures CD8 +spe-
cific T-cell response and does not cover patients 
with rare human leucocyte antigen class I alleles.
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CMV disease in SOT patients depends on several factors, 
among others the transplanted organ, the donor/recip-
ient CMV serology and the immunosuppression therapy 
used.1 2
Depending on each patient’s risk, the prevention 
strategy to be used is defined. There are two types of strat-
egies: universal prophylaxis and pre-emptive treatment. 
Universal prophylaxis consists of the administration of 
antivirals such as ganciclovir or valganciclovir during the 
first months post-transplant. Pre-emptive therapy is based 
on the administration of antivirals once the CMV repli-
cation has been detected in blood or serum, for which it 
is necessary to monitor the patient at regular intervals.2 3
In the particular case of lung transplant recipients, 
both the international and Spanish consensus guidelines 
on the management of CMV infection in SOT patients 
recommend universal prophylaxis in all lung transplant 
recipients of a CMV-positive donor, with the serology of 
the recipient determining the duration of prophylaxis: 
12 months in CMV-negative recipients (D+/R-) and 6 
months in CMV-positive recipients (D+/R+).1 2
However, the application of universal prophylaxis has 
associated risks due to the side effects of prolonged anti-
viral use. The most frequent side effects are leucopenia, 
digestive discomfort (diarrhoea, vomiting, abdominal 
pain) and renal dysfunction. To prevent or reduce the 
adverse effects of these antivirals, recent research has 
focused on the search for immunological biomarkers 
to help identify transplant patients at low risk of CMV 
replication/reactivation in which prophylaxis could be 
reduced or even discontinued. In particular, the moni-
toring of cell-mediated CMV immunity has been shown 
to be useful in guiding clinical decision-making in trans-
planted patients.3–8
Several techniques are currently available to monitor 
cell-mediated immunity to CMV, including the use of 
multimers, intracellular staining, Enzyme-Linked Immu-
nospot assay (ELISPOT) and QuantiFERON-CMV assay 
(QF-CMV). Regardless of the technique used, several 
authors have shown that the presence of cellular immu-
nity to CMV in pre-transplantation or post-transplantation 
is associated with a lower risk of CMV replication and/or 
disease.9–18 Specifically, our group has been working for 
years in the pre-transplant monitoring of cell immunity 
against CMV in SOT patients using the QF-CMV tech-
nique (Qiagen). This is a functional technique that quan-
tifies interferon-γ (IFNG) released by CMV-specific CD8 
+T cells when stimulated with 22 CMV peptides.16 19 Our 
published results indicate that patients with CMV-spe-
cific cell response (QF-CMV Reactive; ≥0.2 IFNG IU/mL) 
prior to transplantation have a lower risk of CMV replica-
tion after transplantation.16
Recently published results of a clinical trial in lung 
transplant recipients have shown that the monitoring of 
CMV-specific cell immunity, also measured by QF-CMV, 
permits individualising the preventive management 
of CMV disease in these transplant recipients.20 The 
patients in the study were randomised to receive standard 
prophylaxis for 5 months or experimental prophylaxis 
guided by QF-CMV. The authors observed that the 
QF-CMV-guided experimental prophylaxis arm had a 
lower incidence of CMV infection than the standard 
prophylaxis arm. Therefore, the standardisation and vali-
dation of these studies have the potential to significantly 
change the monitoring and treatment of CMV infection 
in transplanted patients and further individualise strate-
gies to prevent CMV infection.20 21
Bearing in mind these results, we have formulated a new 
hypothesis based on the fact that lung transplant patients 
who are QF-CMV Reactive at month +3 after transplanta-
tion could benefit from reduced duration prophylaxis, as 
they have specific immunity to maintain the virus under 
control. Thus, by combining a strategy of reduced dura-
tion prophylaxis (henceforth reduced prophylaxis) with 
immunological monitoring of CMV-specific response 
at a later stage would control CMV replication in these 
patients in the same way as the current strategy (prophy-
laxis followed by pre-emptive therapy), while reducing 
the side effects of antivirals since the duration of prophy-
laxis is shorter. The aims of CYTOCOR study are: (1) To 
evaluate the efficacy of reduced prophylaxis (3 months) 
followed by immuno-guided prophylaxis (QF-CMV 
Reactive, cut-off 0.2 IU/mL) to prevent CMV disease 
in R+lung transplant recipients in comparison with 
the usual strategy of universal prophylaxis (6 months) 
followed by pre-emptive therapy for 6 months and (2) To 
assess whether, in the patients of experimental group who 
develop CMV disease, an IFNG cut-off point other than 
0.2 IU/mL could predict protection against the disease 
more reliably.
MEthods And AnAlysIs
design
This is a phase III randomised, open, multicenter, parallel, 
non-inferiority clinical trial. The patients will be assigned 
to two groups (figure 1):
1. Control Group (universal prophylaxis+pre-emptive 
therapy; 6+6): In this patients the recommendation 
of the Spanish Consensus Document1 will be followed 
according to this strategy: (i) universal prophylaxis with 
valganciclovir (900 mg/24 hours, corrected for renal 
function) up to month +6. The use of associated immu-
notherapy (eg, anti-CMV hyperimmune immunoglob-
ulin) will depend on each centre’s clinical practice; 
(ii) pre-emptive therapy guided by viral load from month 
+6 to month +12. For a viral load above >38 copies/mL 
(>35 IU/mL) and depending on each centre’s clinical 
practice, treatment with valganciclovir may be initiated 
(900 mg/12 hours, corrected for renal function). Blips 
must be excluded before starting treatment.
2. Experimental Group (reduced prophylaxis+immu-
no-guided prophylaxis; 3+9): (i) universal prophylaxis 
with valganciclovir (900 mg/24 hours, corrected for 
renal function) up to month +3. The use of associated 
immunotherapy (eg, anti-CMV hyperimmune immu-
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Figure 1 Flow diagram. CMV,cytomegalovirus; QF-CMV, QuantiFERON-CMV.
noglobulin) will depend on each centre’s clinical prac-
tice; (ii) immuno-guided prophylaxis. This will consist of 
a monthly determination of cellular immunity by QF-
CMV from month +3 to month +12. In this group, the 
strategy will be as follows (figure 2):
1. Following the first determination of positive specific 
immunity (QF-CMV Reactive), prophylaxis will be 
discontinued. Monthly monitoring of the specific 
immunity will continue until month +12. Cases in 
which the specific immunity is negative (QF-CMV 
Non-Reactive or Indeterminate) after initiating im-
muno-guided prophylaxis, valganciclovir prophy-
laxis will be resumed.
2. In patients in whom all cell immunity determi-
nations are negative (QF-CMV Non-Reactive or 
Indeterminate), valganciclovir prophylaxis will be 
maintained until month +12.
3. At least one viral replication control will be per-
formed with each cell immunity determination 
(monthly) and if positive (>38 copies/mL or 
>35 IU/mL), will be treated according to each cen-
tre’s clinical practice.
4. If the patient in the experimental group continues 
with prophylaxis at month +12, the prophylaxis 
should be discontinued at this time.
In either of the two groups (control and experi-
mental) and when indicated according to each centre’s 
usual clinical practice, ganciclovir may be used (5 mg/
kg/12 hours, corrected for renal function). All patients 
will be followed up to month +18 post-transplant to study 
CMV disease.
study population and setting
The clinical trial is a multicentre project in which seven 
national lung transplant centres will participate. The trial 
will include lung transplant patients with positive CMV 
serology belonging to the participating centres. Patients 
who meet all the inclusion criteria and no exclusion 
criteria will be prospectively included in the study.
The inclusion and exclusion criteria for the trial are 
described in box 1.
Withdrawal criteria 
Patients may withdraw from the study at any time, for any 
reason and without prejudice to future medical treat-
ment. Patients who do not comply with the study proce-
dure, have not been followed up or for whom no further 
information has become available since the date of with-
drawal or the date of last contact shall be considered a 
study “withdrawal”. The reasons for withdrawal will be 
examined in full accordance with bioethical principles 
regarding the guarantee of patients’ rights and autono-
mous and informed consent. The criteria for withdrawal 
from the study are described below:
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Figure 2 Study design. m, month; PCR, polymerase chain reaction.
box 1 study selection criteria
Inclusion criteria
1. Lung transplant recipients with positive pre-transplant CMV serology
2. Over 18 years of age
3. That the expected time of prophylaxis with valganciclovir is 6 
months post-transplant
4. Patients who have given written informed consent
Exclusion criteria
1. Pre-transplant CMV-seronegative recipients
2. HIV-infected patients
3. Pregnant and/or lactating women
4. Intolerance to valganciclovir/ganciclovir
5. Multivisceral transplant patients
6. Patients who cannot comply with the follow-up protocol
CMV, cytomegalovirus.
1. On patient’s request and withdrawal of patient’s in-
formed consent.
2. Protocol violation or deviation.
3. If considered clinically appropriate by the investigators 
when the patient’s symptoms worsen.
4. Administrative decision by investigators, sponsor or a 
regulatory authority.
5. Loss to follow-up.
6. Serious adverse event or clinically relevant event at the 
discretion of the researcher.
7. Unexpected serious adverse reaction at the discretion 
of the researcher.
8. The endpoint of the study is reached:
 – In the experimental group (3+9): Loss to fol-
low-up/Death/QF-CMV Non-reactive at month 
+12.
 – In the control group (6+6): Loss to follow-up/
Death/CMV replication at month +12.
The investigator shall indicate whether the patient or 
the investigator made the decision to withdraw from the 
study and which of the following possible reasons led to 
the withdrawal:
1. Any patient in either group who develops CMV disease 
(symptomatic replication or organ disease without 
viraemia) will be withdrawn from the study (patients 
who develop asymptomatic replication will not be 
withdrawn from the study; they will be treated and the 
scheduled follow-up will continue).
2. On patient’s request and withdrawal of informed con-
sent.
3. Protocol violation or deviation (eg, non-compliance 
with treatment, need for prohibited treatment, etc).
4. If considered clinically appropriate by the investigators 
when the patient’s medical condition worsens.
5. Administrative decision by investigators, sponsor or a 
regulatory authority.
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Table 1 Definitions included in the study
Type Definition
CMV replication Can be diagnosed by growing 
the virus in vitro, finding 
evidence of viral infection by 
intra-cytoplasmic or intra-nuclear 
inclusions or by antibody-based 
staining techniques for CMV in 
histopathological sections or 
finding evidence of replication 
using nucleic acid based assays 
or antigenaemia studies.
CMV disease Evidence of CMV infection with 
attributable symptoms. CMV 
disease can be sub-classified 
into CMV viral syndrome or 
tissue invasive disease.
Definitive diagnosis of CMV 
pneumonia must be based on 
the histological demonstration 
of CMV invasive disease. 
Nevertheless, for this study we 
also accept the evidence of CMV 
infection (including detection of 
CMV-DNA in bronchoalveolar 
lavage (BAL)) with attributable 
symptoms once other potential 
causes has been ruled out.
CMV, cytomegalovirus.
study variables
Efficacy variables
1. Primary outcome variable: Incidence of CMV disease 
at 18 months post-transplant. “CMV disease” is defined 
as evidence of CMV infection with attributable symp-
toms (table 1). CMV disease can be sub-classified as 
CMV viral syndrome or invasive tissue disease.2
2. Secondary outcome variables: Incidence of CMV rep-
lication (excluding replication blips in periods of pro-
phylaxis). “CMV replication” is defined as a viral load 
greater than 38 copies/mL (equivalent to approxi-
mately 35 IU/mL)(table 1).2
Explanatory variables
The following demographic and clinical information will 
be collected from all the patients: age, sex and baseline 
disease, type of transplant (single lung or double lung), 
pre-transplant CMV serology, donor and recipient HLA 
typing, induction immunosuppressive therapy (dose and 
duration), maintenance immunosuppressive therapy 
(dose and duration), CMV antiviral treatment (dose and 
duration, including immunotherapy), other opportu-
nistic infections not associated with CMV (bacterial, viral 
and fungal), acute or chronic graft rejection (time since 
transplantation, number of episodes and treatment) and 
adverse effects attributable to CMV antiviral treatment 
(total number of granulocyte-colony stimulating factor 
doses required or reduction in immune suppression on 
the basis of low white blood cells/neutrophil count).
randomisation and masking
The number of patients will be 150 (75 in each 
group). Patients who meet the selection criteria will be 
randomised, and may be included in the control group or 
the experimental group. Randomisation will be carried 
out by means of electronic case report forms (eCRFs). 
The ratio will be 1:1 for each group and stratified by 
centres. The study design is open, but the investigator 
will not know the treatment assignment until the patient 
signs the informed consent form and randomisation is 
performed, thus minimising selection bias.
study procedures
The duration of follow-up for each patient will be 18 
months and will start from the moment the patient is 
transplanted. A total of 15 visits will be scheduled during 
the trial: one visit during the first 30 days post-transplant, 
12 monthly visits up to the first 12 months post-trans-
plant, one visit at 15 months post-transplant and one visit 
at 18 months post-transplant. The follow-up visits in the 
Control and Experimental groups will be scheduled as 
they are shown in tables 2 and 3, respectively. All visits 
may be made 7 days before or after the day indicated by 
the protocol without being considered deviation, as they 
will coincide with the visits made following usual clinical 
practice.
Both groups: As for determination of CMV replication, in 
the first 3 months it will not be compulsory to monitor viral 
replication (unless indicated according to the centre’s 
clinical practice) nor will CMV-specific cell immunity be 
determined because both groups are receiving universal 
prophylaxis. It will only be compulsory to draw a sample 
for CMV viral load in patients in which prophylaxis has 
been discontinued. The first determination of CMV viral 
load will coincide with the day prophylaxis is discontinued 
and taken as a baseline determination. In centres where 
CMV viraemia is monitored by antigenaemia assay or the 
viral load is determined in whole blood, an aliquot should 
be sent to the laboratory of the coordinating centre to 
determine the CMV viral load.
Experimental group: To determine the CMV-specific cell 
immunity, all the samples will be sent to the laboratory of 
the coordinating centre for analysis. Depending on the 
results, the following procedures will be performed: (a) If 
the QF-CMV is Reactive (IFNG ≥0.2 UI/mL) at any of these 
visits, valganciclovir prophylaxis will be discontinued; 
(b) If the QF-CMV is Non-Reactive (IFNG <0.2 IU/mL), 
prophylaxis will be continued (or reinitiated if previously 
discontinued) and (c) In those cases in which the patient 
of the experimental group is on prophylaxis until month 
+12, prophylaxis will be discontinued.
statistical analysis
The required sample size for a non-inferiority trial has 
been calculated assuming an 85% success rate of the 
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Table 2 Summary chart of visits (control group)
Procedures
control group
Visit 1
(first 30 days)
Visit 2 to Visit 7
(month +1 to+6)
Visit 8 to Visit 13
(month +7 to +12)
Visit 14 and Visit 15
(month +15 and +18)
Informed consent X
Inclusion/exclusion criteria X
Randomisation X
Medical history/anamnesis X X X X
Physical examination* X X X X
Pregnancy test X
Antiviral prophylaxis X X
CMV PCR sample† X X
Haemogram/biochemistry‡ X X X X
Adverse events/concomitant 
medication
X X X X
*Physical examination: weight, heart rate, blood pressure, temperature, abdominal palpation and presence of oedemas
†CMV PCR will be compulsory when antiviral prophylaxis is discontinued. The first CMV PCR will be performed at Visit 7 (month +6), 
coinciding with the discontinuation of antiviral prophylaxis. At Visits 14 and 15 it will not be compulsory to draw samples for viral load (unless 
indicated according to the center’s clinical practice).
‡Haemogram: red blood cells, haemoglobin, leukocytes, neutrophils and platelets. Biochemistry: alkaline phosphatase, gamma-
glutamyltransferase, alanine aminotransferase, aspartate aminotransferase, C-reactive protein, bilirubin, albumin and creatinine.
CMV, cytomegalovirus; PCR, polymerase chain reaction.
Table 3 Summary chart of visits (experimental group)
Procedures
experimental group
Visit 1
(first 30 days)
Visit 2 to Visit 3
(month +1 to +2)
Visit 4 to Visit 13
(month +3 to +12)
Visit 14 and Visit 15
(month +15 and +18)
Informed consent X
Inclusion/exclusion criteria X
Randomisation X
Medical history/anamnesis X X X X
Physical examination* X X X X
Pregnancy test X
Antiviral prophylaxis† X X X
CMV PCR ‡,§ X X
QF-CMV sample§ X
Haemogram/biochemistry¶ X X X X
Adverse events/concomitant 
medication
X X X X
*Physical examination: weight, heart rate, blood pressure, temperature, abdominal palpation and presence of edemas
†In month +3 post-transplant, the patient will continue with antiviral prophylaxis depending on the QF-CMV results.
‡CMV PCR will be compulsory when antiviral prophylaxis is discontinued. The first CMV PCR will coincide with the day prophylaxis is 
discontinued and will be taken as a baseline determination.
§At Visits 14 and 15 it will not be compulsory to draw samples for viral load or for QF-CMV (unless indicated according to the center’s clinical 
practice)
¶Haemogram: red blood cells, haemoglobin, leukocytes, neutrophils and platelets. Biochemistry: alkaline phosphatase, gamma-
glutamyltransferase, alanine aminotransferase, aspartate aminotransferase, C-reactive protein, bilirubin, albumin and creatinin
CMV, cytomegalovirus; PCR, polymerase chain reaction; QF-CMV, QuantiFERON-CMV.
control group, a non-inferiority margin of 7%, an alpha 
risk of 0.05, a power of 80% (beta risk 0.20) and an esti-
mated follow-up loss of 5%. The total number of patients 
required per group is 75 (total sample of 150 patients).22 
The sample size was determined in order to address 
the primary objective of the study, that is, to evaluate if 
the experimental regimen is not less effective than the 
control regimen (non-inferiority study) in terms of the 
incidence of CMV disease in the 18 months post-trans-
plant (primary endpoint).
Clinical data will be collected by means of eCRFs. All 
analyses will be performed using PASW Statistics software 
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V.15.0 (IBM Corporation) and R software (V.3.5.0). 
Frequencies and percentages will be calculated for the 
qualitative variables and compared using the X2 test or 
Fisher’s test. For quantitative variables, the mean and 
SD will be calculated. Normality will be analysed using 
the Kolmogorov-Smirnov test and comparisons will be 
made using the Student’s t-test or the Mann-Whitney 
test depending on whether or not they follow a normal 
distribution, respectively. For the comparison of three or 
more groups, the analysis of variance (ANOVA) or Krus-
kal-Wallis tests will be performed. The incidence of CMV 
disease according to the strategy used will be calculated 
by Kaplan-Meier curves which will be compared using the 
log-rank test. If patients in the Experimental Group (3+9) 
develop CMV disease, a multivariate Cox proportional 
hazards regression model will be used. The Receiver 
Operating Characteristic (ROC) curve will be used to 
calculate if there is a cut-off in IFNG levels other than 0.2 
UI/mL that could better predict protection against CMV 
disease.
EthICAl IssuEs And dIssEMInAtIon plAn
This clinical trial will be conducted in accordance 
with the protocol, the principles set out in the current 
revised version of the Declaration of Helsinki (Fortaleza, 
2013) and in accordance with the applicable regulatory 
requirements, in particular the ICH Tripartite Guide-
line “Standards of Good Clinical Practice”, Royal Decree 
1090/2015 regulating clinical trials with medicinal prod-
ucts in Spain, and Regulation (EU) No 536/2014 of the 
European Parliament and of the Council of 16 April 2014 
on clinical trials on medicinal products for human use.
The protocol, the informed consent form, the patient 
information form and any documents applicable to the 
study have required approval by the appropriate regula-
tory agencies. The study has been approved by the Coor-
dinating Committee for Biomedical Research Ethics. 
Authorisation has also been obtained from the Spanish 
Agency of Medicines and Medical Devices (AEMPS).
The trial is registered in publicly accessible databases 
such as the Spanish Clinical Studies Registry (REec) and 
ClinicalTrials. gov (NCT03699254).
dIsCussIon
Immunological monitoring of CMV infection in trans-
planted patients has been shown to be useful in identi-
fying patients who are protected against infection by the 
virus after transplantation and in whom antiviral treat-
ment may be reduced or discontinued. However, the 
vast majority of studies that have addressed this issue are 
observational,4–19 and do not provide solid evidence that is 
strong enough for rapid implementation in routine clin-
ical practice. It is therefore a major challenge to perform 
intervention studies to demonstrate that the monitoring 
of cell immunity against CMV in transplanted patients is a 
very useful in routine clinical practice.
In the particular case of lung transplant patients, the 
results of the first clinical trial in these patients in which 
immunological monitoring is used to individualise the 
duration of universal prophylaxis have recently been 
published.20 In this study, patients in the arm with exper-
imental prophylaxis immuno-guided by QF-CMV showed 
a lower incidence of CMV infection than in the arm with 
standard prophylaxis for a duration of 5 months.
However, if the hypothesis of our study is confirmed, 
the duration of CMV antiviral prophylaxis in lung trans-
plant patients could be further shortened, as it could be 
reduced to only 3 months in patients who already present 
specific CMV-specific immunity at 3 months. This would 
reduce the toxicity associated with the prolonged use of 
antivirals and lead to greater economic savings of antiviral 
drugs.
On the other hand, there is scientific evidence of late-
onset CMV disease at 12 months after lung transplanta-
tion.23 Therefore, our study could prove whether in the 
subgroup of patients who reach month +12 without cell 
immunity to the virus (QF-CMV Non-Reactive) have a 
higher incidence of late CMV disease. These results would 
serve to evaluate the possibility of prolonging prophylaxis 
with antivirals in this small subgroup of patients.
As for the technique we intend to use to monitor cell 
immunity against CMV in our study population, we have 
chosen QF-CMV because it is a standardised technique 
with a well-defined cut-off, requires minimal sample 
manipulation, is easy to use, provides negative and posi-
tive controls for each patient and is automatable. Addi-
tionally, our group has used this technique for years and 
we therefore have broad experience and a highly quali-
fied staff.
In conclusion, the CYTOCOR study aims to individu-
alise the management of CMV infection in lung trans-
plant patients by monitoring CMV-specific immunity. If 
our hypothesis is confirmed, the management of CMV 
infection in lung transplant patients could be individu-
alised in such a way that: (1) The toxicity associated with 
the prolonged use of antivirals would be reduced, (2) 
Economic costs would be reduced by decreasing the anti-
viral treatment, (3) Costs of virological monitoring would 
be saved and (4) Morbidity and costs associated with late 
disease would be saved after inadequate discontinuation 
of prophylaxis in these patients.
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